Mark Erlander
About Mark Erlander
Mark Erlander is the CEO of Cardiff Oncology and a seasoned scientist with extensive experience in oncology and biochemistry, holding numerous patents and publications.
Mark Erlander - Chief Executive Officer
Mark Erlander currently serves as the Chief Executive Officer. His career is marked by significant leadership roles and he has held key positions across various esteemed organizations. His tenure in executive and scientific roles demonstrates extensive expertise and a strong leadership record.
Mark Erlander Education and Expertise
Mark Erlander has an impressive academic background in biochemistry and neuroscience. He holds a B.S. in Biochemistry from the University of California, Davis, and an M.S. degree in Biochemistry from Iowa State University. Additionally, he earned a Ph.D. in Neuroscience from the University of California, Los Angeles. This extensive academic foundation has equipped him with deep expertise in scientific research and innovation.
Mark Erlander Career Background
Mark Erlander has a diverse and extensive career in scientific leadership. Before becoming CEO, he served as the Chief Scientific Officer at Cardiff Oncology from March 2013 to May 2020. His previous roles include Chief Scientific Officer at bioTheranostics, a subsidiary of bioMérieux, and Chief Scientific Officer at Arcturus, Inc., which was acquired by bioMérieux in 2008. Earlier in his career, he was involved in drug discovery at Johnson & Johnson from 1994 to 2000 and served as a Postdoctoral Fellow and Assistant Professor at Scripps Research from 1991 to 1994.
Mark Erlander Achievements in Scientific Research
Mark Erlander is a prolific contributor to scientific research and innovation. He holds 44 issued patents and has more than 50 pending patent applications. In addition to his patents, he has co-authored over 90 scientific publications, showcasing his influence and active participation in advancing scientific knowledge.